Apimeds Pharmaceuticals US (APUS) vs Aytu BioPharma (AYTU)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Aytu BioPharma (AYTU) has outperformed Apimeds Pharmaceuticals US (APUS) over the past year, losing 13.5% versus a loss of 70.5%. Aytu BioPharma is the larger company by market cap ($22.3 million vs $8.3 million), about 2.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APUS | AYTU |
|---|---|---|
| Share price | $5.51 | $2.05 |
| Market cap | $8.32M | $22.28M |
| 1-day change | -21.84% | 0.00% |
| YTD return | -66.40% | -21.15% |
| 1-year return | -70.53% | -13.50% |
| 5-year return | — | -96.13% |
| Forward P/E | — | 13.23 |
| EPS (TTM) | $-36.03 | $-1.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $59.70 | $3.07 |
| 52-week low | $1.51 | $1.80 |
| Distance from 52-week high | -90.77% | -33.22% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +371.71% |
| Average volume | 3.66M | 34.22K |
| Shares outstanding | 1.51M | 10.87M |
| Employees | — | 75 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Aytu BioPharma is about 2.7 times larger than Apimeds Pharmaceuticals US by market value ($22.28M vs $8.32M).
- AYTU has outperformed APUS by 57.0 percentage points over the past year.
About Apimeds Pharmaceuticals US
APUS stock →Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure.
Healthcare · Drug Manufacturers - Specialty & Generic
About Aytu BioPharma
AYTU stock →Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age.
Healthcare · Drug Manufacturers - Specialty & Generic · 75 employees
APUS vs AYTU FAQ
Which is bigger, Apimeds Pharmaceuticals US or Aytu BioPharma?
Aytu BioPharma (AYTU) is larger, with a market capitalization of $22.28M compared with $8.32M for Apimeds Pharmaceuticals US (APUS).
Which stock has performed better over the past year, APUS or AYTU?
AYTU returned -13.50% over the past 12 months, compared with -70.53% for APUS (price return, excluding dividends). Past performance does not predict future results.
Are Apimeds Pharmaceuticals US and Aytu BioPharma in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.